Backs FY22 revenue view $5.3B-$5.36B, consensus $5.32B. The company said, "Based on preliminary financial results, the Company is reaffirming its estimated full-year 2022 revenue guidance that was previously provided on November 4, 2022. These preliminary financial results are based on the Company’s current estimate of its results for the year ended December 31, 2022 and remain subject to change based on the completion of closing and review procedures and the execution of the Company’s internal control over financial reporting. Mr. Meggs’ planned departure is not a result of any disagreement regarding the Company’s financial statements or disclosures."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A and Licensing Deals in 2023
- Syneos Health Announces Chief Financial Officer Transition
- Syneos Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Syneos Health downgraded on low earnings visibility at Mizuho
- Syneos Health downgraded to Neutral from Buy at Mizuho
